Editor's Choice

Rosiglitazone: a cautionary tale

BMJ 2010; 341 doi: 10.1136/bmj.c4896 (Published 6 September 2010)
Cite this as: BMJ 2010;341:c4896

This article has a correction

Please see: Editor’s Choice. Rosiglitazone: a cautionary tale

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fiona Godlee, editor, BMJ
  1. fgodlee{at}bmj.com

    This week a BMJ investigation suggests that the diabetes drug rosiglitazone should never have been licensed and should now be withdrawn (doi:10.1136/bmj.c4848).

    The tale of rosiglitazone is a cautionary one from which we must hope the main parties will learn for the future. Hailed as a much needed new approach for patients with type 2 diabetes, the drug was licensed 10 years ago with only limited evidence of its effectiveness and concerns over its safety. While allowing the drug onto the market, the regulators asked the manufacturer GlaxoSmithKline to do additional trials. This the company did while marketing the drug around the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular